ArticleGenomics & informatics2025
Non-variable RNA deletion using the CRISPR-Cas9 technique demonstrated improved outcomes in human intestine single-cell RNA sequencing data, even at half sequencing depths.
Article in Genomics & informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
In single-cell RNA sequencing (scRNA-seq) data, issues related to the high expression of non-variable RNAs often arise due to organ traits or sample quality. Computational methods, such as SoupX (Young (Gigascience 9:giaa151, 2020)), have been used to solve this problem but it may remove biologically relevant data. This study presents a clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9-based method that selectively removes non-variable RNAs. We applied this approach to scRNA-seq data from human intestinal tissues of 17 patients. By targeting non-variable genes, including ribosomal and mitochondrial RNAs, CRISPR-Cas9 treatment effectively reduced their expression, outperforming computational methods in both the number and extent of gene removal. The CRISPR-Cas9 treated samples, sequenced at half the depth compared to untreated samples, maintained comparable sequencing quality, and saturation, demonstrating that this approach can reduce sequencing costs while preserving data quality. Cell type composition and gene expression patterns remained consistent between treated and original datasets, with no unintended gene deletions. Overall, our findings suggest that the CRISPR-Cas9-based method offers a cost-effective solution for improving scRNA-seq data quality, particularly for tissues with high levels of non-variable RNAs, without compromising biological integrity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.